These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1378 related articles for article (PubMed ID: 15741571)

  • 1. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
    Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
    J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing different strategies for colorectal cancer screening in Italy: predictors of patients' participation.
    Senore C; Armaroli P; Silvani M; Andreoni B; Bisanti L; Marai L; Castiglione G; Grazzini G; Taddei S; Gasperoni S; Giuliani O; Malfitana G; Marutti A; Genta G; Segnan N
    Am J Gastroenterol; 2010 Jan; 105(1):188-98. PubMed ID: 19826409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
    van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
    Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening.
    Segnan N; Senore C; Andreoni B; Azzoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; Ederle A; Fantin A; Ferrari A; Fracchia M; Ferrero F; Gasperoni S; Recchia S; Risio M; Rubeca T; Saracco G; Zappa M;
    Gastroenterology; 2007 Jun; 132(7):2304-12. PubMed ID: 17570205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
    Tsoi KK; Ng SS; Leung MC; Sung JJ
    Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial.
    Weissfeld JL; Schoen RE; Pinsky PF; Bresalier RS; Church T; Yurgalevitch S; Austin JH; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Jul; 97(13):989-97. PubMed ID: 15998952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study.
    Gimeno-García AZ; Quintero E; Nicolás-Pérez D; Hernández-Guerra M; Parra-Blanco A; Jiménez-Sosa A
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1062-7. PubMed ID: 19307978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.
    Lieberman DA; Weiss DG;
    N Engl J Med; 2001 Aug; 345(8):555-60. PubMed ID: 11529208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population.
    Graser A; Stieber P; Nagel D; Schäfer C; Horst D; Becker CR; Nikolaou K; Lottes A; Geisbüsch S; Kramer H; Wagner AC; Diepolder H; Schirra J; Roth HJ; Seidel D; Göke B; Reiser MF; Kolligs FT
    Gut; 2009 Feb; 58(2):241-8. PubMed ID: 18852257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in colorectal cancer testing among Medicare subpopulations.
    Fenton JJ; Cai Y; Green P; Beckett LA; Franks P; Baldwin LM
    Am J Prev Med; 2008 Sep; 35(3):194-202. PubMed ID: 18619761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Participation in colorectal cancer screening with FOBT and colonoscopy: an Italian, multicentre, randomized population study.
    Lisi D; Hassan C; Crespi M;
    Dig Liver Dis; 2010 May; 42(5):371-6. PubMed ID: 19747888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
    Quintero E
    Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are we doing enough to screen for colorectal cancer? Findings from the 1999 Behavioral Risk Factor Surveillance System.
    Seeff LC; Shapiro JA; Nadel MR
    J Fam Pract; 2002 Sep; 51(9):761-6. PubMed ID: 12366896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of colorectal cancer screening participation in the United States.
    Ioannou GN; Chapko MK; Dominitz JA
    Am J Gastroenterol; 2003 Sep; 98(9):2082-91. PubMed ID: 14499792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal cancer screening with the addition of flexible sigmoidoscopy to guaiac-based faecal occult blood testing: a French population-based controlled study (Wintzenheim trial).
    Denis B; Gendre I; Aman F; Ribstein F; Maurin P; Perrin P
    Eur J Cancer; 2009 Dec; 45(18):3282-90. PubMed ID: 19665368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of self-reported colorectal cancer screening behavior from a mixed-mode survey of veterans.
    Partin MR; Grill J; Noorbaloochi S; Powell AA; Burgess DJ; Vernon SW; Halek K; Griffin JM; van Ryn M; Fisher DA
    Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):768-76. PubMed ID: 18381474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient preferences for colorectal cancer screening.
    Leard LE; Savides TJ; Ganiats TG
    J Fam Pract; 1997 Sep; 45(3):211-8. PubMed ID: 9300000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
    Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
    Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early detection of colorectal cancer with faecal occult blood test screening.
    Paimela H; Malila N; Palva T; Hakulinen T; Vertio H; Järvinen H
    Br J Surg; 2010 Oct; 97(10):1567-71. PubMed ID: 20603855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.